DIRS.INFO The most relevant business & tech news

☆ 2 health stocks are buys. They've been beaten up enough on Trump's RFK Jr. pick for HHS
▼ + stars: | 2024-11-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Following Monday's trade, Jim Cramer's Charitable Trust will own 550 shares of DHR, increasing its weighting to roughly 3.6% from 3.4%. Since the election, Danaher shares have fallen from $250 each to $230 while Eli Lilly shares have dropped from $806 to $720. LLY YTD mountain Eli Lilly YTD Eli Lilly shares fell from $903 to $846 after a disappointing third-quarter report where inventory destocking of its fast-selling GLP-1 medications caused the company to miss estimates and lower full-year guidance. But the possible appointment of RFK Jr. has created a whole host of uncertainty for Eli Lilly and the drug stocks at large. If you look out to 2026, Lilly shares are trading at roughly 24 times.

Persons: Jim Cramer's, Donald Trump, Robert F, Kennedy Jr, We're, Danaher, Eli Lilly, Bioprocessing, Eli Lilly's, Lilly, Jim Cramer, Jim Organizations: DHR, Care Sector Fund, Department of Health, Human Services, RFK Jr, National Institutes of Health, HHS, CNBC Locations: Danaher

☆ The next big market for weight-loss drugs: children
▼ + stars: | 2024-09-11 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Novo Nordisk's American rival, Eli Lilly, has also been testing obesity-beating drugs for children as young as six. Wegovy and similar drugs for weight loss have become a huge business. The drugs' success has made Novo Nordisk the most valuable company in Europe. AdvertisementChildhood obesityAn FDA approval on weight loss drugs for children could open up a new market for Novo Nordisk. In June, US Sen. Bernie Sanders announced that Novo Nordisk CEO Lars Jørgensen would testify before the committee on September 24 at a hearing focusing on the prices that Novo Nordisk charges Americans for their drugs, Ozempic and Wegovy.

Persons: —, Saxenda, Novo, Claudia Fox, Eli Lilly, Goldman Sachs, Wegovy, Sen, Bernie Sanders, Lars Jørgensen, Sanders Organizations: Service, BMI, Business, FDA, Financial Times, Novo Nordisk, Centers for Disease Locations: Madrid, Europe

☆ After a busy week of stock trades, we're looking ahead to some key inflation data
▼ + stars: | 2024-08-11 | by ( Morgan Chittum | ) www.cnbc.com time to read: +5 min

Looking back, quarterly earnings also played a key role in big stock moves for the portfolio. Looking ahead, we'll see an update on some key inflation data, plus a closer look at the state of the housing and retail sectors. ET: Producer Price Index Earnings: Home Depot (HD), Pandora (PANDY), Nu Holdings (NU), Sea Limited (SE) Wednesday, August 14 8:30 a.m. ET: Consumer Price Index Earnings: Tencent Holdings (TCEHY), Cisco (CSCO), UBS (UBS), JD.com (JD) Thursday, August 15 8:30 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Eli Lilly, Walt, Jim Cramer, we've, JD.com, Jim Cramer's, Jim, Spencer Platt Organizations: Dow Jones, Dow, Nasdaq, Walt Disney, Microsoft, Ford Motor, Wynn Resorts, DuPont, Devices, Procter, Gamble, Club, Abbott Laboratories, Federal, Traders, Sun Life, Nu Holdings, Sea, Tencent Holdings, Cisco, UBS, Philadelphia Fed, Walmart, Materials, Deere & Co, Ross Stores, Lenovo, Housing, Jim Cramer's Charitable, CNBC, New York Stock Exchange, Getty Locations: U.S, Dover, Wells Fargo, Nextracker, Eaton

☆ Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
▼ + stars: | 2024-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

Shares of Eli Lilly closed more than 9% higher on Thursday. That has forced Eli Lilly and its rival Novo Nordisk to invest heavily to boost manufacturing. "We just see unbelievable demand, and we're not even trying that hard to promote this drug," Eli Lilly CEO David Ricks told CNBC in an interview. Eli Lilly said sales were largely driven by higher demand for Mounjaro and Zepbound as production increases improved supply in the U.S. With a market cap of more than $730 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, Eli Lilly's, we're, David Ricks, Ricks, Zepbound, Mounjaro, Wegovy Organizations: U.S, Novo Nordisk, Food, CNBC, LSEG Locations: U.S, United States, Novo

☆ Here are JPMorgan's top drug stock picks into earnings
▼ + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.

Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo

☆ We're hiking our price targets on Meta, Eli Lilly, and 3 other stocks on recent runs higher
▼ + stars: | 2024-07-09 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

AMZN YTD mountain Amazon YTD We begin with Amazon 's move, which has been fueled by strength in its three core businesses. GOOGL YTD mountain Alphabet YTD Alphabet has been gaining steam in recent months on similar cloud tailwinds but also improving sentiment around its AI capabilities. META YTD mountain Meta Platforms YTD Meta Platforms ' stock has fully recovered all of its first-quarter earnings losses. LLY YTD mountain Eli Lilly YTD We are also increasing our Eli Lilly price target – taking it to $1,000 per share from $850. PANW YTD mountain Palo Alto Networks YTD One more stock we're raising our price target for is Palo Alto Networks .

Persons: Eli Lilly, Eli Lilly YTD, There's, donanemab, We're, Jim Cramer's, Jim Cramer, Jim, Beata Zawrzel Organizations: Palo Alto Networks, Amazon, Jefferies, Facebook, Alto Networks, CNBC, Google, Nurphoto, Getty Locations: CIOs, United States, Indiana, Palo

☆ Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
▼ + stars: | 2024-06-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

Eli Lilly presented the new data from the trials at the American Diabetes Association's 84th Scientific Sessions in Orlando, Florida, on Friday. An estimated 80 million patients in the U.S. experience the disease, Eli Lilly said in a press release. Disease resolution for OSA is defined as a patient having fewer than five AHI events per hour, according to Eli Lilly. Eli Lilly on Friday reiterated that Zepbound met the main goal of the trial, which was reducing AHI events. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity.

Persons: Eli Lilly, Zepbound, Patrik Jonsson, Jonsson, Leonard Glass, —, Eli Lilly's Organizations: Food and Drug Administration, Diabetes, CNBC, OSA, FDA Locations: Orlando , Florida, U.S

☆ 10 things to watch in the stock market Thursday including the latest call on Nvidia
▼ + stars: | 2024-06-20 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Stifel raised its price target on Nvidia to $165 a share from $114, implying nearly 22% upside from Tuesday's close. Keybanc raised its price target on Club holding Meta Platforms to $540 a share from $475, citing a "meaningful uptick" in ad prices. Tesla price target lowered to $227 a share from $293 at RBC Capital, but analysts maintained their outperform rating on the electric vehicle maker's stock. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Stifel, Olive Garden, Piper Sandler, Keefe, Eli Lilly, Tesla, Uber, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Nvidia, Microsoft, Darden, LongHorn, Honeywell, CAES, Holdings, Accenture, Citigroup, Citi Services, Citi . Club, RBC Capital, RBC, Jim Cramer's Charitable, CNBC Locations: U.S

☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
▼ + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com time to read: +10 min

Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.

Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey

☆ Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street's expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range. Shares of Eli Lilly jumped almost 8% in premarket trading Tuesday. With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, LSEG, They're Organizations: Analysts, LSEG Locations: San Diego , California, U.S

☆ Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. Zepbound was more effective than a placebo at reducing the severity of obstructive sleep apnea, or OSA, in patients with obesity after a year, according to preliminary data from both trials. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity. Zepbound has slipped into shortages since receiving approval in the U.S. for weight management in November.

Persons: Eli Lilly’s, Eli Lilly, Zepbound, Dr, Jeff Emmick, Eli Lilly's Organizations: U.S . Food, Drug Administration, FDA, OSA Locations: New York City, U.S

☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
▼ + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah

☆ Jim Cramer says Microsoft's unbundling of Teams and Office is good news for this portfolio stock
▼ + stars: | 2024-04-02 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "We should all expect sell-offs after a bountiful period that started in October," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Eli Lilly, Eli Lilly's, Eli Lilly's GLP, Jim, Slack, Jim Cramer's Organizations: CNBC, Citigroup, Citi, Microsoft, Club

Berenberg increased its price target on Eli Lilly on the back of expected strong sales of its weight loss drug, Zepbound. The firm kept its $21 price target, saying shares are "ready to inflect" with hardware cost deflation and investment tax credit boosting growth. Danely's $820 price target on the buy-rated blockbuster chipmaker suggests 3.6% potential upside for shares since Monday's close. — Pia Singh 5:38 a.m.: Berenberg hikes Eli Lilly price target Eli Lilly has been on a tear this year, and Berenberg expects even more gains from here. Analyst Kerry Holford reiterated his buy rating on the stock and raised his price target to $850 from $680.

Persons: Berenberg, Eli Lilly, John Hodulik, Hodulik, — Pia Singh, Wells, Steven Cahall, Cahall, ROKU, Fred Imbert, BofA Evercore, James West, Christopher Danely, Danely, Goldman Sachs, Edward Jones, James Shanahan, Goldman, Marcus, Apiro Dounls, Sunoco, Kerry Holford, Holford, Zepbound Organizations: CNBC, pharma, Nvidia, Citi, Sunoco, NuStar Energy, Netflix, UBS, Vizio, CTV, ISI, BofA, BofA Evercore ISI, Bank of America, Micron Technology, NuStar, SUN Locations: Wells, Sunrun, Monday's

☆ In this fast-paced bull market, we're increasing our Club price targets on 4 stocks
▼ + stars: | 2024-02-15 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Following last week's $120-per-share price target hike to $750 on strong earnings, we're raising our PT again Thursday to $850. Even at our new $850 price target, Lilly shares still represent a lower PEG than we've seen historically but that provides some margin of safety. Costco price target hike to $770 from $680 Costco also trades at a premium valuation, but we think it's warranted due to the company's reliability and consistency. Salesforce price target hike to $320 from $275 Salesforce is a Club name we recently highlighted in our 10 undervalued stocks commentary . Palo Alto Networks price target change pending Lastly, we are aware that our price target on Palo Alto Networks requires an update as well.

Persons: It's, Eli Lilly, Lilly, Salesforce, –, There's, Jim Cramer's, Jim Cramer, Jim, Robert Nickelsberg Organizations: Wall, PT, Novo Nordisk, Costco, Microsoft, Broadcom, UBS, VMware, JPMorgan, Palo Alto, Palo Alto Networks, Palo, CNBC, Getty Locations: GLP, AVGO, Palo Alto, Palo, New York City

☆ Wall Street gives 2 of our healthcare stocks well-deserved price target bumps
▼ + stars: | 2024-02-07 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. GE Healthcare fell slightly Wednesday, holding on to most of Tuesday's almost 11.7% surge. The biggest price target boost for GE Healthcare came from Piper Sandler, going to $94 per share from $84 while reiterating its buy-equivalent rating. Goldman Sachs, which has a hold rating on Eli Lilly, bumped its price target to $650 a share from $600. The GE Healthcare scanner is called the Revolution CT. Martin Schutt | picture alliance | Getty Images

Persons: Eli Lilly, tirzepatide, Lilly, it's, Piper Sandler, —, Mizuho, Wells Fargo, Evercore, Eli Lilly's, Lilly's, Eli, Truist, Cantor Fitzgerald, Morgan Stanley, Goldman Sachs, Jim Cramer's, Jim Cramer, Jim, Martin Schutt Organizations: GE Healthcare, Club, GE, Mizuho Securities, Electric, BMO Capital Markets, Truist Securities, CNBC, Bank of America, Barclays, Getty Locations: Amgen, China, Eli Lilly's, Wells Fargo, Jena , Germany

☆ Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
▼ + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. Zepbound, which won approval from U.S. regulators in early November, raked in $175.8 million in sales for the fourth quarter. Shares of Eli Lilly were up 5% in premarket trading Tuesday. With a market cap of roughly $673 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.Eli Lilly will hold an earnings call with investors at 10:00 a.m.

Persons: Eli Lilly, Eli Lilly's, Mounjaro Organizations: LSEG, FactSet Locations: San Diego , California, U.S

☆ Wall Street says Big Tech needs to take a breather after huge run. Here's our take
▼ + stars: | 2024-02-06 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "This is a consolidation day," Jim Cramer said Tuesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, We're, Jim, We're bullish, Jim Cramer's Organizations: CNBC, Big Tech, Citigroup, GE Healthcare

☆ We're raising our price target on Eli Lilly by $120 after its excellent quarter
▼ + stars: | 2024-02-06 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

Bottom line Eli Lilly delivered a strong report Tuesday. Still, it's not a surprise to see shares of Eli Lilly fall nearly 2% Tuesday, to around $694 each. Despite doubling manufacturing capacity year over year in 2023, Eli Lilly said demand for its GLP-1s is "likely to outpace supply" this year. We're raising our Eli Lilly price target to $750 a share from $630, while reiterating our 2 rating on the stock, meaning we'd wait for a pullback before adding to our position. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly's, Lilly's, Eli Lilly, Mounjaro, Zepbound, it's, —, Jim Cramer, Anat Ashkenazi, NASH, Lilly, Jim, Jardiance, Verzenio, Trulicity, donanemab, Ashkenazi, Jim Cramer's, George Frey Organizations: Revenue, LSEG, U.S, Novo Nordisk, Food and Drug Administration, Analysts, Investors, FDA, CNBC, Bloomberg, Getty Locations: Mounjaro's, U.S, Mounjaro, Trulicity, Provo , Utah

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

☆ FDA finds new manufacturing lapses at Eli Lilly plant
▼ + stars: | 2024-01-19 | by ( ) www.cnbc.com time to read: +4 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey, March 5, 2021. U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters. They included problems in tracking manufacturing process and quality controls, as well as lapses in its calibration of equipment and failure to properly maintain facilities and equipment, the inspection report shows. Yet the Indianapolis-based drugmaker has been cited multiple times for manufacturing problems at its U.S. plants over the last few years, Reuters has reported. Three regulatory experts who reviewed the new inspection report described the most recent lapses as serious.

Persons: Eli Lilly, Lilly, Steven Lynn, Lynn Organizations: Company, U.S, Reuters, The, The U.S . Food, Drug, FDA, U.S . Department of Justice, Justice Department, Manufacturing Locations: Branchburg , New Jersey, The U.S, Lilly's, , New Jersey, U.S, Indianapolis

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. The company declined to comment on the plans but news conferences are planned in Alzey, where sources say the plant will be built, and Berlin on Friday. Other people familiar with the plans told Reuters that at least 1,000 jobs would be created. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Andreas Rinke, Ludwig Burger, Thomas Escritt, Madeline Chambers, Miranda Murray, Christina Fincher Organizations: Company, REUTERS, Basf, Reuters, BASF, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, BERLIN, Germany, Alzey, Berlin, U.S, Ukraine, European, Indianapolis, Danish, Eisai

☆ Eli Lilly plans to invest 2 bln euros in new German plant -source
▼ + stars: | 2023-11-16 | by ( ) www.reuters.com time to read: +1 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsCompanies Eli Lilly and Co FollowBERLIN, Nov 16 (Reuters) - U.S. pharma company Eli Lilly (LLY.N) plans to invest 2 billion euros ($2.17 billion) in a new plant in Alzey, western Germany, a source close to the negotiations told Reuters on Thursday. Separately, people familiar with the plans told Reuters that at least 1,000 jobs would be created. Reuters had reported on Wednesday that the pharma group intended to invest in Germany after Eli Lilly called a news conference for Friday but few details were available. ($1 = 0.9217 euros)Reporting by Andreas Rinke and Rene Wagner Writing by Madeline Chambers Editing by Kirsti Knolle and Miranda MurrayOur Standards: The Thomson Reuters Trust Principles.

Persons: Eli Lilly, Mike Segar, Andreas Rinke, Rene Wagner, Madeline Chambers, Kirsti Knolle, Miranda Murray Organizations: Company, REUTERS, . pharma, Reuters, pharma, Thomson Locations: Branchburg , New Jersey, Alzey, Germany

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsBERLIN, Nov 15 (Reuters) - U.S. pharma company Eli Lilly (LLY.N) plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a news conference for Friday. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates. The group's market value has ballooned to around $580 billion, up more than 65% so far this year.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Ludwig Burger, Thomas Escritt, Chizu Nomiyama, Jane Merriman Organizations: Company, REUTERS, Rights, . pharma, Reuters, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, Germany, Rhineland, Palatinate, U.S, Ukraine, European, Indianapolis, Danish, Eisai

Search resuls for: "Eli Lilly P"

25 mentions found